{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-076346","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.252482+00:00","generated_at":"2026-06-13T14:42:28.658688+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cellectar presents iopofosine I 131 MM data: 32% ORR at optimal dose >60 mCi TAD","bullets":["Overall response rate 23% in 64 evaluable patients; 32% ORR at optimal >60 mCi TAD dose.","Clinical benefit rate 75% and disease control rate 85.7% at >60 mCi TAD.","Triple-class refractory patients achieved 46% ORR (median PFS 3.4 mo); quad-class 50% ORR.","Grade 3/4 cytopenias common (62.5% thrombocytopenia, anemia, neutropenia); no off-target toxicities.","Drug given as four 15-min IV infusions over 3 months with low-dose dexamethasone."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-076346","json":"https://secwatch.observer/filing/0001104659-23-076346.json","markdown":"https://secwatch.observer/filing/0001104659-23-076346.md","text":"https://secwatch.observer/filing/0001104659-23-076346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923076346/0001104659-23-076346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923076346/tm2320208d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:42:28.658688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}